Latest KFF Health News Stories
CBO’s Report On Single-Payer Health Care Holds More Questions Than Answers
The Congressional Budget Office report does clearly communicate that shifting to this type of health system would be a complicated process.
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health care policy stories each week, so you don’t have to.
Newsom: California Leads On Prescription Drugs
California Gov. Gavin Newsom claims that his state is “leading the nation in holding drug companies accountable and fighting prescription drug prices.” Is that really the case?
Klobuchar Wants To Stop ‘Pay-For-Delay’ Deals That Keep Drug Prices High
It’s as shady as it sounds.
Pain Clinics’ Doctors Needlessly Tested Hundreds Of Urine Samples, Court Records Show
Whistleblower lawsuits accuse Tennessee chain of bilking millions from Medicare for unnecessary urine drug tests.
Amid Opioid Prescriber Crackdown, Health Officials Reach Out To Pain Patients
After dozens of health care workers were charged with illegally prescribing opioids in Appalachia, local health agencies are trying to make sure chronic pain patients don’t fall through the cracks.
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don’t have to.
Mulvaney: Trump Brought Down Drug Prices For The First Time In 50 Years
It’s “within spitting distance of something that’s true,” said one health economist. But our fact check found it wasn’t quite there.
The Blame Game: Everyone And No One Is Raising Insulin Prices
During Wednesday’s House subcommittee hearing on insulin price hikes, drug makers and benefits managers pointed fingers at each other for the last decade’s 300% price increase, frustrating congressional representatives.
Can Someone Tell Me What A PBM Does?
The Senate Finance Committee’s third drug-pricing hearing focused on pharmacy benefit managers, and was more of a fact-finding mission on how these companies operate than a debate about policy proposals.
Consumers Rejected Drug Plan That Mirrors Trump Administration Proposal
What to know about PBMs and rebates ahead of the Senate drug price hearing on — you guessed it — PBMs.
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don’t have to.
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don’t have to.
Analysis: Why Americans Shouldn’t Feel Grateful For $137 Insulin
Only by the bizarre logic of the U.S. pharmaceutical industry does this drug count as any kind of generic.
Must-Reads Of The Week (Some Flying Below The Radar)
Executive editor Damon Darlin takes a spin as host of “The Friday Breeze,” whirling through a week of health care news so you don’t have to.
Podcast: KHN’s ‘What The Health?’ The Karma Of Cutting Medicare
Stephanie Armour of The Wall Street Journal, Alice Ollstein of Politico and Rebecca Adams of CQ Roll Call join KHN’s Julie Rovner to discuss the suggested cuts to health programs in President Donald Trump’s budget proposal, the latest on lawsuits challenging work requirements for Medicaid enrollees and the FDA’s crackdown on e-cigarettes. Plus, for extra credit, the panelists recommend their favorite health policy stories of the week.
How Much Difference Will Eli Lilly’s Half-Price Insulin Make?
Eli Lilly released a half-price generic version of its own short-acting insulin. At $137.35 per vial, the generic insulin is priced at about the same level as Humalog was in 2012.
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don’t have to.
Ciudades y condados seguirán importando medicamentos, a pesar de alertas de la FDA
Varios estados, entre ellos Florida y Nueva York, dijeron que continuarán usando una compañía canadiense para ofrecer a sus empleados medicamentos recetados a bajo precio.
Pacientes experimentan con drogas recetadas para luchar contra la vejez
Aún no se han realizado ensayos clínicos rigurosos a gran escala para estudiar el proceso de envejecimiento. Así y todo, pacientes experimentan con drogas para detener el paso del tiempo.
